Sector News

Charles River Labs cuts jobs as it closes San Diego site

April 3, 2019
Life sciences

After a number of pacts and buyouts over the past few years, Charles River Labs is cutting staff at one of its California sites.

According to a recent WARN notice, the CRO is cutting 24 employees from its San Diego site.

Charles River confirmed the cuts to FierceCRO today: “As part of our continuing efforts to streamline operations and enhance efficiencies, we have made the decision to close our research model production facility in San Diego and relocate all services and production to our Hollister site. Charles River is committed to maintaining its world-class client service and will ensure that the site closure will not impact availability or service.

“As part of this difficult but necessary decision, we are working with employees to ensure appropriate support and resources are in place as they seek new employment opportunities, both within and outside the company.”

Despite these cuts, over the past few months CRL has been spending, snapping up companies and making deals, including just two months back buying up early-stage CRO Citoxlab. A month before, it also went all-in for British CRO KWS BioTest in a £15 million ($20 million) deal. It’s also penned a new pact with Crown Bioscience for expanded access to the Zucker Diabetic Sprague-Dawley rat model.

By Ben Adams

Source: Fierce Biotech

3 responses to “Charles River Labs cuts jobs as it closes San Diego site

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend